Entrada Therapeutics slumps as FDA puts DMD therapy trial application on hold

Entrada Therapeutics

19/12/2022 22:39

** Shares of Entrada Therapeutics Inc  TRDA.O  drop ~32% to
$13.50 after market 
    ** Co receives a clinical hold notice from U.S. FDA
regarding application for study of its potential treatment of
Duchenne muscular dystrophy (DMD), ENTR-601-44  
    ** FDA indicated it will provide an official clinical hold
letter to co within 30 days; will work to address FDA's concerns
regarding the application - TRDA    
    ** DMD is a rare disorder that affects muscles, leading to
muscle wasting that gets worse over time
    ** As of last close, stock was up ~16% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))